



Oncology Office Hematology Requisition

Client Information	Patient Information
Required Information Account #: Account Name:	Last Name: ☐ Male ☐ Female First Name: M.I. Medical Record #:
Street Address:	Date of Birth: mm / dd / / yyyy Other Pt ID/Acct #:
	Client represents it has obtained informed consent from patient to perform the services described herein.
City, ST, ZIP:	Specimen Information
Phone: Fax:	
Additional Reporting Fax:	☐ Mobile Phlebotomy Request NeoGenomics will reach out to patient to schedule appointment - Patient Phone:
Requisition Completed by: Date:	Specimen ID:Block ID:Fixative/Preservative:
Ordering Physician: NPI #: (please print: Last, First):	Fixative/Preservative: / dd / yyyy Collection Time: AM PM
Treating Oncologist/Physician: NPI #:	Retrieved Date: mm / dd / yyyy
(please print: Last, First): The undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are medi-	Hospital Discharge Date: mm / dd / yyyy Body Site:
cally necessary for the care/treatment of this patient.	□ Primary □ Metastasis – If Metastasis, list Primary:
Authorized Signature: Date:	☐ Bone Marrow [must provide CBC Report]:
Billing Information	Green Top(s) Purple Top(s) Core Biopsy Clot
Required: Please include face sheet and front/back of patient's insurance card.	Peripheral Blood: Green Top(s) Other
Patient Status (Must Choose 1): Rill to:	☐ Smears: Air Dried Stained (type of stain)
□ Non-Hospital Patient □ Insurance □ Patient/Self-Pav	□ Slides # Unstained Stained □ H&E □ Paraffin Block(s) #:
OP Molecular to MCR, all other testing to Client	Choose best block (for global molecular/NGS testing only)
☐ Hospital Patient (out) See back for definitions. ☐ Bill charges to other Hospital/Facility:	Submit ≤4 blocks. Blocks will be combined for molecular testing when necessary.
	For all other testing, specify which block to use for each if sending multiple blocks. See back for details.
Prior Authorization # See neogenomics.com/billing for more info.	Specimen Retrieval
Clinical Information	Client Services will request specimen from Pathology site.
Required: Please attach patient's pathology report (required), clinical history, and other applicable report(s).	Pathology Site:
ICD 10 (Diagnosis) Code/Narrative (Required):	Address:Fax:Fax:
Reason for Referral:	
□ New Diagnosis □ Relapse/Refractory □ Monitoring □ MRD	Required Items
Bone Marrow Transplant	☐ Patient Demographics ☐ Pathology Report ☐ Copy of Insurance Card ☐ Clinical History
□ None □ Autologous □ Allogeneic □ Sex Mismatch	☐ CBC Within Last 30 Days ☐ Relevant Treatment History
□ Paraffin block for Morphology to follow Lymphoma Consult □ Lymph Node/Tissue for Lymphoma* *Split fresh specimens to RPMI and formalin □ Paraffin block for Morphology to follow or marked by the client) to provide of the materials submitted. Please attach CBC for Blood and E	
Morphology	Molecular Genetics
☐ Blood and/or Bone Marrow	□ ABL1 Kinase Domain (Gleevec® resistance) □ JAK2 V617F - Qualitative □ If negative, reflex to JAK2 Exon 12-13
NeoTYPE [®] and Neo Comprehensive™ Cancer Profiles	☐ BCR-ABL1 Standard p210, p190 ☐ If negative, reflex to CALR
☐ATL/Peripheral T-Cell Lymphoma Profile ☐ Follicular Lymphoma Profile (FFPE only)	☐ BCR-ABL1 Standard p210, p190 with reflex to ABL1 Kinase Domain if positive ☐ JAK2 V617F - Quantitative
☐ ALL Profile ☐ Lymphoid Disorders Profile	☐ BCR-ABL1 Standard p210, p190 with reflex to ☐ KIT (c-KIT)
☐ AML Prognostic Profile ☐ Lymphoma Profile ☐ Lymp	BCR-ABL1 Non-Standard p230 if negative ☐ MPL Mutation Analysis ☐ BCR-ABL1 Non-Standard p230 ☐ MPN JAK2 V617F with Sequential Reflex
☐ CLL Profile	☐ BCR-ABL1 Non-Standard p230 ☐ MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, & MPL
Add IgVH Mutation Analysis	☐ BTK Inhibitor Acquired Resistance Panel ☐ MYD88 Mutation Analysis
☐ Neo Comprehensive – Heme Cancers ☐ Neo Comprehensive – Heme Cancers + FLT3 by PCR*	☐ Calreticulin (CALR) Mutation Analysis ☐ NPM1 MRD Analysis ☐ NPM1 Mutation Analysis ☐ NPM1 Mutation Analysis
□ Neo Comprehensive – Henre Cancers + PETS by PCK □ Neo Comprehensive – Myeloid Disorders	☐ CXCR4 Mutation Analysis ☐ PML- RARA, t(15;17)
□ Neo Comprehensive – Myeloid Disorders + FLT3 by PCR*	☐ FLT3 Mutation Analysis ☐ Rapid AML Therapeutic Panel ☐ RUNX1-RUNX1T1 (AML1-ETO), t(8:21)
*Please see back page for detailed info on Intended Use and Billing for FLT3 by PCR	□ IDH1/IDH2 by PCR □ RUNX1-RUNX111 (AML1-ETO), t(8;21) □ IgH Clonality by NGS □ T-Cell Receptor Gamma
Flow Cytometry	Baseline testing of original primary sample required T-Cell Receptor Beta
Please attach CBC with all flow requests on blood (required).	□ IgVH Mutation Analysis □ TP53 Mutation Analysis □ Other □ O
Diagnostic/Prognostic Panels MRD Panels	HemeFISH®
☐ Standard L/L Panel (24 Markers) ☐ B-ALL MRD (Bone Marrow)	☐ Anaplastic Large Cell Lymphoma (ALCL) ☐ High-Grade B-Cell Lymphoma Reflex
☐ Extended L/L Panel (31 Markers) ☐ B-ALL MRD (Peripheral Blood)	□ ALL - Adult □ Low-Grade/Small B-Cell Lymphoma
☐ High Sensitivity PNH ☐ CLL MRD ☐ Myeloma (MM) MRD	☐ ALL - Pediatric ☐ MDS Extended ☐ MDS Standard
	│ □ B-ALL, Ph-Like ☐ MDS Standard ☐ MPN
Cytogenetics	☐ AML Non-Favorable Risk ☐ NHL
Oncology Chromosome Analysis	☐ BCR/ABL1/ASS1 t(9;22) ☐ Plasma Cell Myeloma ☐ Do not reflex to IgH Complex
☐ Reflex to FISH if cytogenetics is normal (reflex FISH panel must be selected)	□ CLL □ Do not reflex to 1gH Complex □ Bosinophilia □ Plasma Cell Myeloma IgH Complex
☐ Reflex to FISH if cytogenetics is incomplete (<20 metaphases)	☐ High-Grade/Large B-cell Lymphoma ☐ Plasma Cell Myeloma Prognostic Panel
☐ MDS Standard FISH ☐ MDS Extended FISH	☐ Reflex to BCL6/MYC, IGK/MYC, IGL/MYC if ☐ Other
☐ WIDS Exterided FISH	MYC+ and IGH/MYC- Plasma Cell Enrichment will be performed on all bone marrow samples having plasma cell FISH tests.

Specimen Requirements

Refrigerate specimen if not shipping immediately and use cool pack during transport. Please call the Client Services team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 3. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order. This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Additional Specimen Information

If submitting multiple blocks, clients must indicate either "Choose best block (global molecular/NGS testing only)", or assign the selection of blocks to individual tests. If multiple blocks are sent without a selection, they will be held until clarification is provided. Please call the Client Services team with any questions regarding specimen information.

Definitions of Patient Status for Specimen Origin

Non-Hospital Patient: Patient is not registered at a hospital (neither an in-patient nor out-patient)

Hospital Patient (in): Patient is registered and admitted to a hospital overnight

Hospital Patient (out): Patient is registered and admitted to a hospital, then discharged before the end of the day

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com/test-menu.

Test Notations

Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

EIGH

Plasma cell myeloma FISH panels: Plasma cell enrichment will be performed on bone marrow samples having plasma cell FISH. Sample should be received at NeoGenomics Laboratories within 72 hours of collection.

FLT3 Testing with NeoTYPE® or Neo Comprehensive™ profiles

The FLT3 Mutation Analysis test is available as client-bill only when ordered with NeoTYPE or Neo Comprehensive. The Molecular case reports separately from the NeoTYPE or Neo Comprehensive Profile (which also includes FLT3 gene by NGS) for the purpose of prompt therapy selection in patients with a new diagnosis of AML.